Glucose-Lowering and the Risk of Cardiovascular Events With Antidiabetic Therapies: A Systematic Review and Additive-Effects Network Meta-Analysis.

ABSTRACT:

Aim

To assess the impact of the HbA1c levels achieved with antidiabetic therapies (ADTs) on the risk of MACE.

Methods

A systematic search was performed in PubMed, Cochrane, and ClinicalTrials. gov for RCTs published up to March 2022 reporting the occurrence of MACE and all-cause mortality in individuals with T2DM treated with all marketed ADTs, including a sample size ≥100 individuals in each study arm and follow-up ≥24 weeks. A systematic review and additive-effects network meta-analysis with random effects and a multivariate meta-regression were utilized to assess the impact of achieved HbA1c on incident MACE.

Results

We included 126 RCTs with 143 treatment arms, 270,874 individuals, and 740,295 individuals-years who were randomized to an active treatment vs. contro

SUBMITTER: de Carvalho LSF 

PROVIDER: S-EPMC9098935 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature